Johan Frostegård Selected Research

lacidipine

1/2014	Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development.
1/2012	IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL.
9/2006	Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension.
11/2003	Circulating oxidized low-density lipoprotein is increased in hypertension.
9/2003	Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension.
9/2002	Circulating heat shock protein and heat shock protein antibody levels in established hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johan Frostegård Research Topics

Disease

34	Atherosclerosis 01/2022 - 01/2001
31	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 08/2002
18	Inflammation (Inflammations) 01/2022 - 08/2002
14	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 09/2003
13	Hypertension (High Blood Pressure) 01/2020 - 01/2001
12	Atherosclerotic Plaque (Atheroma) 07/2020 - 01/2005
7	Rheumatoid Arthritis 01/2021 - 09/2007
6	Myocardial Infarction 01/2022 - 12/2003
6	Dyslipidemias (Dyslipidemia) 01/2011 - 08/2002
5	Rupture 11/2017 - 01/2005
4	Stroke (Strokes) 01/2022 - 01/2010
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2021 - 12/2003
4	Carotid Artery Diseases 03/2015 - 11/2003
4	Thrombosis (Thrombus) 01/2014 - 09/2004
4	Insulin Resistance 01/2011 - 12/2003
3	Obesity 10/2021 - 05/2018
3	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 09/2005
3	Type 2 Diabetes Mellitus (MODY) 12/2020 - 11/2015
3	Infections 03/2020 - 09/2009
3	Pain (Aches) 07/2018 - 06/2012
2	Neoplasms (Cancer) 10/2021 - 01/2018
2	Ischemic Stroke 12/2016 - 04/2009
2	Hyperlipidemias (Hyperlipidemia) 12/2016 - 11/2015
2	Nephritis 03/2015 - 09/2003
2	Necrosis 11/2011 - 03/2006
1	Uremia 01/2021
1	Chronic Disease (Chronic Diseases) 12/2020
1	Body Weight (Weight, Body) 12/2020
1	Rheumatic Diseases (Rheumatism) 01/2020
1	Mixed Connective Tissue Disease (MCTD) 01/2020
1	Lupus Nephritis 01/2020
1	Fatigue 07/2018
1	Overweight 05/2018
1	Genetic Risk Score 01/2018
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018
1	Spondyloenchondrodysplasia 01/2017
1	Coronary Disease (Coronary Heart Disease) 12/2016
1	Angina Pectoris 12/2016
1	Diabetes Complications 11/2015
1	Diabetes Mellitus 03/2015

Drug/Important Bio-Agent (IBA)

41	AntibodiesIBA 01/2022 - 01/2001
32	Immunoglobulin M (IgM)IBA 01/2022 - 09/2006
30	Phosphorylcholine (Phosphocholine)IBA 01/2022 - 09/2006
23	oxidized low density lipoproteinIBA 01/2022 - 01/2001
9	LipidsIBA 01/2020 - 09/2002
8	C-Reactive ProteinIBA 09/2021 - 12/2003
8	Malondialdehyde (Propanedial)IBA 01/2021 - 01/2016
8	LDL Lipoproteins (beta Lipoproteins)IBA 11/2017 - 07/2003
7	AutoantibodiesIBA 01/2021 - 08/2002
6	CholesterolIBA 01/2022 - 09/2003
6	Phospholipids (Phosphatides)FDA LinkGeneric 02/2015 - 08/2002
6	Annexin A5IBA 01/2015 - 01/2005
6	lacidipineIBA 01/2014 - 09/2002
6	CytokinesIBA 10/2013 - 01/2001
4	Immunoglobulin G (IgG)IBA 01/2022 - 03/2020
4	Triglycerides (Triacylglycerol)IBA 12/2020 - 08/2002
4	ApolipoproteinsIBA 01/2015 - 01/2011
4	Antiphospholipid AntibodiesIBA 06/2007 - 01/2005
3	Insulin (Novolin)FDA Link 12/2020 - 11/2006
3	HDL LipoproteinsIBA 05/2018 - 09/2003
3	PhosphatidylserinesIBA 01/2017 - 11/2013
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2015 - 09/2002
3	Cardiolipins (Cardiolipin)IBA 01/2014 - 01/2013
3	Proteins (Proteins, Gene)FDA Link 12/2013 - 11/2009
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2013 - 09/2003
3	ChromatinIBA 04/2012 - 03/2006
2	Interleukin-6 (Interleukin 6)IBA 09/2021 - 12/2003
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 06/2012
2	HDL CholesterolIBA 12/2020 - 08/2002
2	Prednisolone (Predate)FDA LinkGeneric 01/2020 - 09/2007
2	AlbuminsIBA 08/2019 - 12/2016
2	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 10/2013 - 01/2001
2	LDL CholesterolIBA 01/2009 - 09/2004
1	Atorvastatin (Lipitor)FDA Link 09/2021
1	HDL-triglycerideIBA 12/2020
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 07/2020
1	SubtilisinIBA 07/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 07/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Transcription Factor 3IBA 01/2018
1	AntigensIBA 11/2017
1	Chaperonin 60IBA 11/2017
1	Interferon Type IIBA 01/2017
1	Tartrate-Resistant Acid PhosphataseIBA 01/2017
1	Human Serum Albumin FDA LinkGeneric 12/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 11/2015
1	coenzyme Q10 (CoQ10)IBA 11/2015
1	Complement C3 (C3 Complement)IBA 03/2015
1	Antimalarials (Antimalarial Agents)IBA 03/2015
1	Complement C4 (Complement Component 4)IBA 03/2015
1	Secretory Phospholipases A2IBA 01/2015
1	Leukotriene B4IBA 08/2014
1	Therapeutic UsesIBA 08/2014
1	Blood Proteins (Serum Proteins)IBA 08/2014
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 08/2014
1	Anti-Idiotypic AntibodiesIBA 01/2014

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2011